lung cancer
Conditions
Interventions
observation group:None
Sponsors
West China School of Medicine/West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or clinically confirmed diagnosis of NSCLC; refusal of open surgery or assessed as ineligible for thoracoscopic resection by multidisciplinary team (MDT). 2. Aged 18–75 years, either sex. 3. ECOG performance status = 6 months, and has provided written informed consent. 4. Determined by the investigator to be eligible for local ablation therapy (radiofrequency ablation, microwave ablation, or cryoablation). 5. Participants should have complete clinical data, including but not limited to age, sex, family history, imaging findings, and histopathological results.
Exclusion criteria
Exclusion criteria: 1. History of surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy within 3 months prior to enrollment. 2. History of malignancy other than the current NSCLC diagnosis; autoimmune disease; or pregnancy or lactation. 3. Severe dysfunction of vital organs (including but not limited to the heart, liver, and kidneys) precluding tolerance of examinations and treatment. 4. Multiple nodules that cannot be completely treated during the current procedure. 5. Negative methylation test results at all three time points (preoperative, 1 day, and 1 month postoperative). 6. Likely inability to complete follow-up during the study, or any other condition deemed by the investigator to make the subject unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-Year Disease-Free Survival (DFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival(OS);Sensitivity, Specificity, and AUC of ctDNA Methylation Markers; | — |
Countries
China
Contacts
Public ContactDan Liu
West China School of Medicine/West China Hospital, Sichuan University
Outcome results
None listed